PBE vs. BNO
PBE (Invesco Dynamic Biotechnology & Genome ETF) and BNO (United States Brent Oil Fund LP) are both exchange-traded funds - PBE is a Health & Biotech Equities fund tracking the Dynamic Biotech & Genome Intellidex Index (AMEX), while BNO is a Oil & Gas fund tracking the Front Month Brent Crude Oil. Both are passively managed. Over the past 10 years, PBE returned 7.34%/yr vs 13.38%/yr for BNO. At a 0.13 correlation, their price movements are largely independent. PBE charges 0.59%/yr vs 0.90%/yr for BNO.
Performance
PBE vs. BNO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PBE achieves a -1.43% return, which is significantly lower than BNO's 86.76% return. Over the past 10 years, PBE has underperformed BNO with an annualized return of 7.34%, while BNO has yielded a comparatively higher 13.38% annualized return.
PBE
- 1D
- -2.22%
- 1M
- 1.51%
- YTD
- -1.43%
- 6M
- -0.16%
- 1Y
- 28.65%
- 3Y*
- 9.70%
- 5Y*
- 2.89%
- 10Y*
- 7.34%
BNO
- 1D
- 0.76%
- 1M
- -7.65%
- YTD
- 86.76%
- 6M
- 83.45%
- 1Y
- 89.50%
- 3Y*
- 27.10%
- 5Y*
- 23.77%
- 10Y*
- 13.38%
PBE vs. BNO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | -1.43% | 24.84% | 1.10% | 3.71% | -10.83% | 1.54% | 25.66% | 18.65% | -0.19% | 22.28% |
BNO United States Brent Oil Fund LP | 86.76% | -5.44% | 9.67% | -3.43% | 35.25% | 62.34% | -38.23% | 36.01% | -15.30% | 15.43% |
Correlation
The correlation between PBE and BNO is -0.32, meaning they tend to move in opposite directions. This is especially valuable for risk management - when one declines, the other has historically tended to hold steady or rise.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.32 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.13 |
Correlation (5Y) Calculated over the trailing 5-year period | -0.02 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.08 |
Correlation (All Time) Calculated using the full available price history since Jun 3, 2010 | 0.13 |
The correlation between PBE and BNO shifts across timeframes, from -0.32 (1 year) to 0.13 (all time), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PBE vs. BNO — Risk / Return Rank
PBE
BNO
PBE vs. BNO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and United States Brent Oil Fund LP (BNO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PBE | BNO | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.55 | 2.17 | -0.63 |
Sortino ratioReturn per unit of downside risk | 2.33 | 2.68 | -0.35 |
Omega ratioGain probability vs. loss probability | 1.27 | 1.37 | -0.10 |
Calmar ratioReturn relative to maximum drawdown | 2.62 | 5.39 | -2.78 |
Martin ratioReturn relative to average drawdown | 7.37 | 10.23 | -2.86 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PBE | BNO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.55 | 2.17 | -0.63 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.13 | 0.68 | -0.55 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.30 | 0.37 | -0.07 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.14 | +0.18 |
Drawdowns
PBE vs. BNO - Drawdown Comparison
The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum BNO drawdown of -87.06%. Use the drawdown chart below to compare losses from any high point for PBE and BNO.
Loading charts...
Drawdown Indicators
| PBE | BNO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.69% | -87.06% | +41.37% |
Max Drawdown (1Y)Largest decline over 1 year | -11.73% | -17.87% | +6.14% |
Max Drawdown (3Y)Largest decline over 3 years | -22.43% | -23.75% | +1.32% |
Max Drawdown (5Y)Largest decline over 5 years | -34.71% | -33.70% | -1.01% |
Max Drawdown (10Y)Largest decline over 10 years | -37.84% | -75.18% | +37.34% |
Current DrawdownCurrent decline from peak | -5.55% | -12.04% | +6.49% |
Average DrawdownAverage peak-to-trough decline | -16.24% | -40.18% | +23.94% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.17% | 9.43% | -5.26% |
Volatility
PBE vs. BNO - Volatility Comparison
The current volatility for Invesco Dynamic Biotechnology & Genome ETF (PBE) is 5.33%, while United States Brent Oil Fund LP (BNO) has a volatility of 15.03%. This indicates that PBE experiences smaller price fluctuations and is considered to be less risky than BNO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PBE | BNO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.33% | 15.03% | -9.70% |
Volatility (6M)Calculated over the trailing 6-month period | 13.30% | 36.08% | -22.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 18.67% | 41.56% | -22.89% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 22.52% | 35.37% | -12.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.91% | 36.68% | -11.77% |
PBE vs. BNO - Expense Ratio Comparison
PBE has a 0.59% expense ratio, which is lower than BNO's 0.90% expense ratio.
Dividends
PBE vs. BNO - Dividend Comparison
PBE's dividend yield for the trailing twelve months is around 1.07%, while BNO has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BNO United States Brent Oil Fund LP | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PBE Invesco Dynamic Biotechnology & Genome ETF | 1.07% | 1.00% | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% |
Frequently Asked Questions
PBE and BNO have a correlation of -0.32, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BNO has higher volatility (15.03%) compared to PBE (5.33%). In terms of maximum drawdown, PBE dropped -45.69% vs BNO's -87.06%.
On 10-year performance, BNO leads with 13.38% vs 7.34% for PBE. On fees, PBE is cheaper at 0.59% per year. On volatility, PBE has been the lower-risk option at 5.33%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, BNO has performed better with a 13.38% return vs 7.34%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
PBE is cheaper with a 0.59% expense ratio, compared with 0.90% for BNO.
PBE has the higher dividend yield at 1.07%, compared with 0.00% for BNO.
PBE is categorized as Health & Biotech Equities, while BNO is Oil & Gas. PBE tracks Dynamic Biotech & Genome Intellidex Index (AMEX), while BNO tracks Front Month Brent Crude Oil. They also come from different issuers: Invesco and Concierge Technologies. Their fees differ too: 0.59% for PBE and 0.90% for BNO.
BNO currently has the higher Sharpe Ratio (2.17 vs 1.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PBE and BNO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer